January 02, 2026

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

Conexiant

December 23, 2025

FDA OKs First Oral GLP-1 for Obesity

An oral GLP-1 option entered obesity care with outcomes similar to injectable therapy.

Conexiant

December 17, 2025

First Inhaled ED Treatment Gets Green Light for Trials

Beta1's novel delivery system promises 10-minute onset, launching phase I trials in Taiwan next year.

Conexiant

December 16, 2025

FDA OKs Addyi for Postmenopausal Women

Flibanserin approved to treat hypoactive sexual desire disorder in postmenopausal patients under 65

Conexiant

December 15, 2025

Doctors Push Back on FDA Antidepressant Fears

After an FDA roundtable raised alarms about antidepressant use in pregnancy, physicians warn the rhetoric could fuel fear, stigma, and dangerous gaps in care.

KFF Health News

November 21, 2025

Which Antidepressants Shift Physiology?

Researchers found differences in how antidepressants affect weight, blood pressure, heart rate, and other physiological parameters.

Conexiant

November 18, 2025

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Conexiant

November 10, 2025

FDA Proposes Removal of Box Warnings

The FDA proposed updates to menopausal hormone therapy labeling to reflect current evidence on benefits and risks.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant